8-K: Acasti Pharma Reports Year-End Results, GTX-104 Trial On Track for 2025 NDA Submission

Acasti Pharma announced its fiscal year 2024 financial results and provided a business update, highlighting the progress of its GTX-104 clinical trial and a projected cash runway into the second quarter of 2026.

Summary

• Acasti Pharma reported a net loss of $12.9 million for the fiscal year ended March 31, 2024, a significant decrease from the $42.4 million loss in the previous year.
• The company's research and development expenses decreased to $4.7 million from $10.0 million year-over-year, primarily due to a strategic realignment.
• General and administrative expenses also decreased to $6.4 million from $7.6 million, reflecting cost reductions from restructuring.
• Acasti's cash and cash equivalents stood at $23.0 million as of March 31, 2024, compared to $27.9 million the previous year.
• The company expects its cash runway to extend into the second calendar quarter of 2026.
• Patient enrollment in the pivotal STRIVE-ON Phase 3 safety trial for GTX-104 is on track, with a potential NDA submission to the FDA anticipated in the first half of calendar 2025.
• The company completed a $7.5 million private placement equity financing in September 2023.
• Acasti is prioritizing the development of GTX-104, a novel injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
• The addressable market for GTX-104 in the United States is estimated to be about $300 million.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with significant progress in the GTX-104 trial and improved financial metrics, but the company is still operating at a loss and has deprioritized other assets.

Positives

• The company has significantly reduced its net loss year-over-year.
• Acasti has extended its cash runway into the second quarter of 2026, providing financial stability.
• The STRIVE-ON trial is progressing as planned, with a potential NDA submission in the first half of 2025.
• The company successfully completed a $7.5 million private placement.
• Acasti has reduced operating expenses through strategic realignment.
• GTX-104 has a large addressable market in the US, estimated at $300 million.

Negatives

• The company reported a net loss of $12.9 million for the fiscal year ended March 31, 2024.
• Cash and cash equivalents decreased from $27.9 million to $23.0 million year-over-year.
• The company has deprioritized the development of GTX-102 and GTX-101.

Risks

• The success and timing of regulatory submissions for GTX-104 are uncertain.
• Changes to clinical trial designs and regulatory pathways could impact the timeline.
• Legislative, regulatory, political, and economic developments could affect the company.
• Actual costs associated with clinical trials may differ from management's expectations.
• The company's future success is heavily reliant on the success of GTX-104.

Future Outlook

Acasti anticipates a potential NDA submission for GTX-104 in the first half of calendar 2025 and expects its cash runway to extend into the second calendar quarter of 2026.

Management Comments

• Prashant Kohli, CEO of Acasti, stated that the company continued to execute its focused strategy around GTX-104.
• Mr. Kohli believes the STRIVE-ON trial is on track for a potential NDA submission to the FDA in the first half of calendar 2025.
• Mr. Kohli noted that the company's balance sheet was enhanced by the $7.5 million private placement and disciplined execution of the strategic realignment plan.

Industry Context

Acasti is focused on developing treatments for rare and orphan diseases, which aligns with a growing trend in the biopharmaceutical industry. The company's focus on GTX-104 for aSAH addresses a significant unmet medical need, as current treatments have limitations. The company's strategy of prioritizing GTX-104 and deprioritizing other assets is a common approach for smaller biopharma companies with limited resources.

Comparison to Industry Standards

• Acasti's focus on a rare disease like aSAH is similar to companies like Biohaven, which developed Nurtec ODT for migraine, a condition with a large unmet need.
• The company's reduction in operating expenses is a common strategy for biopharma companies in the clinical stage, similar to how companies like Cassava Sciences have managed their spending.
• The projected cash runway into the second quarter of 2026 is a positive sign, as many biopharma companies struggle with funding, similar to the challenges faced by companies like Amylyx Pharmaceuticals.
• The estimated $300 million addressable market for GTX-104 is a significant opportunity, comparable to the market potential for other orphan drugs developed by companies like Sarepta Therapeutics.

Stakeholder Impact

• Shareholders may view the progress of the GTX-104 trial and improved financial metrics positively.
• Employees may be impacted by the strategic realignment and restructuring.
• Patients with aSAH may benefit from the potential approval of GTX-104.
• Creditors may be reassured by the extended cash runway.

Next Steps

• Continue patient enrollment in the STRIVE-ON Phase 3 safety trial.
• Prepare for a potential NDA submission to the FDA in the first half of calendar 2025.
• Monitor cash runway and manage expenses to ensure operations are funded into the second calendar quarter of 2026.
• Potentially out-license or sell GTX-102 and GTX-101.

Key Dates

Keywords

Acasti Pharma, GTX-104, aSAH, Nimodipine, Phase 3 Trial, NDA Submission, Financial Results, Biopharma, Orphan Drug, STRIVE-ON